Drug Overview

The HDAC inhibitor OBP-801 (also known as Spiruchostatin A or YM753) is an investigational, potent, and selective small-molecule inhibitor of the histone deacetylase (HDAC) family of enzymes. It belongs to the class of cyclic lipopeptides, a group of natural products originally isolated from the bacterium Pseudomonas sp.

OBP-801 is a “next-generation” epigenetic modifier. It is designed to target the epigenetic mechanisms that cancer cells use to silence tumor-suppressor genes. Unlike earlier HDAC inhibitors, OBP-801 is noted for its high potency at nanomolar concentrations and its relatively long-lasting effects on gene expression.

Generic Name: OBP-801 (Spiruchostatin A).
Drug Class: Histone Deacetylase (HDAC) Inhibitor / Epigenetic Modifier.
Target: HDAC Class I (specifically HDAC 1, 2, and 3).
Route of Administration: Intravenous (IV) infusion (currently being explored in clinical settings).
FDA Approval Status: Investigational. As of March 2026, OBP-801 is not FDA-approved. It is currently undergoing early-phase clinical trials (Phase I/II) for patients with advanced solid tumors and hematologic malignancies who have failed standard therapies.

What Is It and How Does It Work? (Mechanism of Action)

OBP-801 works by modifying the “packaging” of DNA to reactivate the body’s natural cancer-fighting genes.

Epigenetic Regulation and HDACs

In healthy cells, DNA is wrapped around proteins called histones. When these histones are “acetylated” (tagged with an acetyl group), the DNA is loose, allowing genes to be read. Histone deacetylases (HDACs) are enzymes that remove these tags, causing the DNA to wrap tightly, which “silences” the genes. Cancer cells often overproduce HDACs to shut down genes that would normally stop the tumor from growing.

Molecular Level Mechanisms

Selective Enzyme Inhibition: OBP-801 enters the cancer cell and binds specifically to the active site of Class I HDAC enzymes.
Histone Hyperacetylation: By blocking these enzymes, OBP-801 causes acetyl groups to accumulate on the histones. This keeps the chromatin structure “open.”
Reactivation of Tumor Suppressors: The open structure allows the cell’s machinery to reach and “turn back on” silenced tumor-suppressor genes, such as p21 (which stops cell division) and Bax (which triggers cell death).
Induction of Apoptosis: The resulting shift in gene expression triggers programmed cell death (apoptosis) specifically in malignant cells.
Synergy with Other Agents: OBP-801 has been shown to enhance the sensitivity of cancer cells to other treatments, such as radiation or platinum-based chemotherapy, by making the DNA more accessible to those agents.

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for OBP-801.

Clinical research is primarily focused on the following areas:

Advanced Solid Tumors: Including breast, lung, and colorectal cancers.
Hematologic Malignancies: Investigated for potential use in certain leukemias and lymphomas.
Combination Therapy: Studied for its ability to overcome drug resistance when paired with targeted therapies or immunotherapy.

Dosage and Administration Protocols

Because OBP-801 is an investigational drug, the dosage is determined strictly by clinical trial protocols to establish safety and efficacy.

Treatment Detail	Research Specification (Phase I/II)
Route	Intravenous (IV) Infusion.
Dosing Schedule	Often explored in cycles (e.g., once weekly for 3 weeks followed by 1 week off).
Potency	OBP-801 is highly potent; clinical doses are typically in the microgram-to-milligram range per square meter of body surface area (mg/m²).
Pre-medication	May require anti-emetics to manage potential nausea.

Clinical Efficacy and Research Results

As of early 2026, research results highlight OBP-801’s potential in treating “resistant” cancers.

Potency Comparisons: Preclinical studies have shown that OBP-801 is significantly more potent than first-generation HDAC inhibitors like Vorinostat, requiring much lower concentrations to achieve the same tumor-killing effect.
Overcoming Resistance: In laboratory models of breast cancer, OBP-801 successfully reactivated genes that had become resistant to hormone therapy.
Safety Profile: Early Phase I data suggest that OBP-801 has a manageable safety profile, with researchers focusing on identifying the “Maximum Tolerated Dose” (MTD) that avoids significant impact on healthy blood cells.

Safety Profile and Side Effects

Like other HDAC inhibitors, OBP-801 affects the expression of many genes, which can lead to systemic side effects.

Common Side Effects:

Gastrointestinal Distress: Nausea, vomiting, and diarrhea.
Fatigue: A common systemic response to epigenetic modifiers.
Myelosuppression: A temporary drop in blood counts (neutrophils and platelets), which increases the risk of infection and bruising.

Serious Risks:

Cardiotoxicity: Some HDAC inhibitors are known to affect the heart’s electrical rhythm (QT prolongation). Patients in OBP-801 trials undergo frequent EKGs to monitor heart health.
Electrolyte Imbalance: Potential changes in potassium or magnesium levels.

Research Areas

.HDAC-inhibitor class has recognized potential for enhancing somatic cell reprogramming and directing stem-cell differentiation in regenerative medicine. Because HDAC inhibitors can “open up” the genome, researchers are investigating whether low doses of OBP-801 can help convert adult cells back into pluripotent stem cells or “prime” stem cells to differentiate more effectively into specific tissues. This research is vital for developing new ways to repair damaged organs after cancer treatment.

Patient Management and Practical Recommendations

Pre-treatment Tests:

Baseline EKG: To monitor for potential heart rhythm changes.
Complete Blood Count (CBC): To establish baseline blood cell levels.
Metabolic Panel: To monitor liver and kidney function.

Precautions:

Pregnancy: OBP-801 can cause significant fetal harm; strict birth control is required for both male and female patients during treatment.
Drug Interactions: Inform your oncology team of all other medications, especially those known to affect heart rhythms.

“Do’s and Don’ts” List:

DO report any heart palpitations, dizziness, or fainting immediately.
DO stay well-hydrated to help your kidneys process the drug.
DON’T ignore a fever or signs of infection; even a minor fever can be serious if your white blood cell counts are low.
DON’T start any new supplements or over-the-counter drugs without consulting your oncologist.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. HDAC inhibitor OBP-801 is an investigational agent and is not approved by the US FDA for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified hematologist-oncologist regarding your diagnosis and treatment options.